JAZZ (Jazz Pharmaceuticals plc) Stock Financials & Earnings

JAZZJazz Pharmaceuticals plc

Mkt Cap$12B

Healthcare·Biotechnology·🇮🇪 Ireland·NASDAQ

Revenue (TTM)$4.3B

Net Income (TTM)-$356M

EPS (TTM)-$5.84

Free Cash Flow (TTM)$1.2B

Gross Margin88.2%

Op. Margin5.3%

Net Margin-8.3%

FCF Margin29.2%

P/S Ratio (TTM)2.7x

P/E Ratio (TTM)—

YoY Rev Growth+4.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$893M	$764M	$126M
Q2 23	$957M	$860M	$158M
Q3 23	$972M	$870M	$172M
Q4 23	$1.0B	$905M	$122M
Q1 24	$902M	$806M	$66M
Q2 24	$1.0B	$914M	$199M
Q3 24	$1.1B	$943M	$260M
Q4 24	$1.1B	$959M	$191M
Q1 25	$898M	$793M	-$56M
Q2 25	$1.0B	$929M	-$686M
Q3 25	$1.1B	$868M	$58M
Q4 25	$1.2B	$1.2B	$909M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter	Defitelio/Defibrotide	Epidiolex/Epidyolex	High Sodium AG Oxybate Product Royalty Revenue	Other Products	Other Royalty And Contract Revenues	Rylaze/Enrylaze	Sativex	Vyxeos	Xyrem	Xywav	Zepzelca	Ziihera
Q1 23	$39M	$189M	$2M	$3M	$6M	$86M	$7M	$37M	$178M	$278M	$67M	—
Q2 23	$46M	$202M	$6M	$3M	$5M	$102M	$3M	$34M	$160M	$327M	$70M	—
Q3 23	$48M	$214M	$29M	$3M	$5M	$105M	$5M	$30M	$125M	$332M	$78M	—
Q1 24	$48M	$199M	$50M	$4M	$10M	$103M	$3M	$32M	$64M	$315M	$75M	—
Q2 24	$45M	$247M	$54M	$3M	$6M	$108M	$6M	$43M	$62M	$368M	$81M	—
Q3 24	$66M	$252M	$58M	$2M	$7M	$99M	$5M	$34M	$58M	$388M	$86M	—
Q4 24	$58M	$275M	$55M	$3M	—	$101M	$5M	$53M	$49M	$401M	$78M	—
Q1 25	$41M	$218M	$49M	$5M	$9M	$94M	$5M	$30M	$37M	$345M	$63M	$2M
Q2 25	$48M	$252M	$54M	$4M	$6M	$101M	$5M	$45M	$35M	$415M	$75M	$6M
Q3 25	$52M	$303M	$53M	$2M	$9M	$100M	$5M	$38M	$36M	$431M	$79M	$8M
Q4 25	$59M	$287M	$56M	$3M	—	$108M	$2M	$35M	$38M	$465M	$90M	$9M

Revenue by Geography

Quarter	Europe	Other Countries	United States
Q1 23	$66M	$17M	$810M
Q2 23	$59M	$13M	$885M
Q3 23	$69M	$19M	$885M
Q1 24	$71M	$22M	$808M
Q2 24	$82M	$17M	$925M
Q3 24	$77M	$24M	$954M
Q4 24	$82M	$33M	$974M
Q1 25	$84M	$16M	$798M
Q2 25	$83M	$27M	$936M
Q3 25	$86M	$19M	$1.0B
Q4 25	$88M	$33M	$1.1B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$1.2B	$0	$1.2B
Q2 23	$1.3B	$80M	$1.4B
Q3 23	$1.3B	$250M	$1.6B
Q4 23	$1.5B	$120M	$1.6B
Q1 24	$1.4B	$375M	$1.8B
Q2 24	$1.4B	$625M	$2.0B
Q3 24	$2.2B	$400M	$2.6B
Q4 24	$2.4B	$580M	$3.0B
Q1 25	$1.9B	$710M	$2.6B
Q2 25	$1.2B	$480M	$1.7B
Q3 25	$1.2B	$810M	$2.0B
Q4 25	$1.4B	$1.1B	$2.4B

Shares Outstanding

Revenue Per Employee

Revenue / Employee